Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

Gut

Volumn 39, Issue 1, 1996, Pages 82-86

  Lofberg R ^a   Rutgeerts, P ^b   Malchow, H ^c   Lamers, C ^d   Danielsson, A ^e   Olaison, G ^f   Jewell, D ^g   Ostergaard Thomsen O ^h   Lorenz Meyer, H ⁱ   Goebell, H ^l   Hodgson, H ^j   Persson, T ^k   Seidegard C ^k  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Akademisches Lehrkrankenhaus   (Germany)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g RADCLIFFE INFIRMARY   (United Kingdom)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ Stadsiches Krankhs Friedrichshafen   (Germany)

^j HAMMERSMITH HOSPITAL   (United Kingdom)

^k ASTRAZENECA R AND D   (Sweden)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; TREATMENT PLANNING;

EID: 8944242602     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.1.82     Document Type: Article

References (12)

1. Meyers S, Sachar DB. Medical management of Crohn's disease. Hepatogastroenterology 1990; 37: 42-55.
2. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979; 77: 847-69.
3. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistence and dependency in Crohn's disease. Gut 1994; 35: 360-2.
5. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
6. Greenberg G, Feagan B, Martin F, Sutherland LR, Thomson ABR, Williams N, et al. Oral budesonide for the treatment of active Crohn's disease. N Engl J Med 1994; 331: 836-41
7. Edsbäcker S, Wollmer P, Nilsson A, Nilsson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993; 104: A695.
8. Van den Berg JHM, Mol ChR, Deelder RS, Thijssen JHH. A quantitative assay of cortisol in human plasma by high performance liquid chromatography using a selective chemically bonded stationary phase. Clin Chim Acta 1977; 78: 165-72.
9. Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Bouhnik Y, Veyrac M, et al. Mesalamine in Crohn's disease patients with prednisolone induced remission: effect on steroid weaning and remission maintenance in the year after weaning. A placebo-controlled, multicenter study. Gastroenterology 1995; 108: A878.
10. Sutherland LR, Martin F, Bailey RJ, Fedorak R, Dallaire C, Rossman R, et al. 5-aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn's disease. Gastroenterology 1995; 108: A924.
11. Christy NP. Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. N Engl J Med 1992; 326: 266-7.
12. Löfberg R, Østergaard Thomsen O, Langholz E, Schiöler R, Danielsson A, Suhr O, et al. A comparative study of budesonide versus prednisolone retention enema in active distal ulcerative colitis. A Scandinavian multicenter study. Aliment Pharmacol Ther 1994; 8: 623-9.